



RO-9187

Catalog No: tcsc0954

且	Available Sizes
Size: 5	āmg
Size:	L0mg
Size: 5	50mg
	Specifications
CAS N 87670	
Formu	
Pathw Anti-in	ray: fection
Targe HCV	t:
Purity >98%	/ Grade:
Solub	ility:

Observed Molecular Weight:

284.23

10 mM in DMSO

Product Description

RO-9187 is a potent inhibitor of **HCV** virus replication with an ${
m IC}_{f 50}$ of 171 nM.

IC50 & Target: IC50: 171 nM (HCV)^[1]

In Vitro:





RO-9187 is excellent substrates for deoxycytidine kinase and is phosphorylated with efficiencies up to 3-fold higher than deoxycytidine. RO-9187 inhibits RNA synthesis by HCV polymerases from either HCV genotypes 1a and 1b or containing S96T or S282T point mutations with similar potencies, suggesting no cross-resistance with either R1479 (4´-azidocytidine) or 2´-C-methyl nucleosides. The formation of RO-9187-TP increased in a time- and dose-dependent manner. The maximal triphosphate concentration at 24 h is 87 pmol/106 cells with half-maximal triphosphate formation achieved at 12 μ M RO-9187^[1].

In Vivo: Plasma exposures of RO-9187 in rats increase in a dose-dependent manner between 10 and 2000 mg/kg after oral dosing. Plasma concentrations of 1.4 and 26 μ M (390 and 7454 ng/mL) are achieved in rats and dogs at the 10 mg/kg dose level, respectively. Plasma concentrations up to 57 μ M are achieved in rats dosed with 2000 mg/kg/day^[1].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!